Urinary bladder disorder

Researchers test whether four cycles of dose-dense MVAC chemotherapy, given with G-CSF support, can shrink or eliminate muscle-invasive bladder cancer before radical surgery. The trial enrolls 24 adults with locally advanced urothelial carcinoma of the bladder who are fit for cis…

This early-phase trial tested enfortumab vedotin, a drug placed directly into the bladder via a catheter, in 37 people with a type of bladder cancer that did not respond to standard BCG therapy. The main goals were to check safety and side effects, and to see if the drug could he…

This phase II trial tested the immunotherapy drug pembrolizumab (Keytruda) alone or with another agent in 296 people with high-risk non-muscle-invasive bladder cancer that did not respond to standard BCG therapy. Participants received the drug intravenously every three weeks. The…

This early-stage trial tests a new type of immunotherapy called 4SCAR-T cells in 20 people with advanced bladder cancer that has spread and no longer responds to standard treatments. The cells are genetically modified to recognize and attack cancer cells. The study aims to see if…

This study tested several immunotherapy-based drug combinations in 272 people with advanced bladder cancer that had worsened after platinum chemotherapy. The goal was to see which combinations were safest and most effective at shrinking tumors or slowing the disease. Participants…

This study followed 598 women who received the Altis Single Incision Sling, a minimally invasive mesh device, to treat stress urinary incontinence. Researchers tracked how well the sling worked and monitored safety over 12 and 36 months after implantation. The goal was to see if …

This study looked at whether giving radiation therapy after bladder removal surgery could help prevent cancer from coming back in the pelvis. It included 14 people with advanced bladder cancer. The trial was stopped early, so we don't have clear answers on whether the radiation h…

This phase 2 trial tested whether adding the immunotherapy avelumab to standard chemotherapy (gemcitabine-cisplatin) helps people with advanced bladder cancer that has spread. The study planned to enroll 65 patients but was terminated early. Researchers measured tumor shrinkage a…

This study aimed to see if a mistletoe extract placed directly into the bladder could delay cancer return better than standard chemotherapy in 174 people with early-stage bladder cancer. The trial was stopped early, so results are limited. The approach focuses on controlling the …

This early-phase trial tested the drug plinabulin combined with radiation and immunotherapy in 19 people with advanced cancers (like lung, bladder, or melanoma) that had stopped responding to standard immunotherapy. The goal was to see if the combination was safe and could shrink…

This small study tested whether giving the drug sacituzumab govitecan before surgery could help people with a rare type of muscle-invasive bladder cancer. The drug targets cancer cells and delivers chemotherapy directly to them. Only 4 people took part before the study was stoppe…

This study tested a new type of radiation therapy that adapts daily to the patient's anatomy, combined with chemotherapy, for muscle-invasive bladder cancer. The goal was to see if this approach could lower severe bowel and bladder side effects compared to standard radiation. How…

This phase 1 study tested the cancer drug pazopanib in 18 frail elderly patients (aged 75+) with metastatic cancers like kidney, lung, or breast cancer. The goal was to find the highest safe dose by starting at 400 mg daily and increasing if tolerated. The study was terminated ea…

This early study tested adding a testosterone-lowering drug (degarelix) to standard chemotherapy for people with muscle-invasive bladder cancer that has testosterone receptors. Only 2 people enrolled before the study was stopped. The goal was to see if the combination could elimi…

This early-phase trial tested a new drug called nanrilkefusp alfa, which helps activate immune cells, both alone and combined with the immunotherapy pembrolizumab. It included 115 people with various advanced solid tumors that had stopped responding to standard treatments. The st…

This study tested an experimental drug called enfortumab vedotin, alone or with other cancer drugs, in people with advanced bladder or urinary tract cancer. The goal was to see if the drug could shrink tumors and control the disease. The trial included 348 participants but was te…

This early-phase study tested a new drug called PF-07921585, given alone or with another drug (sasanlimab), in adults with advanced solid tumors like lung, bladder, kidney, melanoma, head & neck, or colorectal cancer. The goal was to check safety and find the right dose. Only 4 p…

This study tested a combination of two drugs, selinexor and pembrolizumab, in people with advanced bladder cancer who either couldn't take the standard chemo drug cisplatin or whose cancer got worse after cisplatin. The goal was to find the best dose and see if the combo could sh…

This early-phase trial tested an experimental drug called OC-001, given alone or with the immunotherapy avelumab, in 73 people with various advanced or metastatic cancers (like lung, breast, and bladder cancer). The main goals were to check safety and how the drug moves through t…

This study tested a combination of two drugs, futibatinib and pembrolizumab, in 43 people with advanced or metastatic bladder cancer who could not receive standard chemotherapy. The goal was to see if the combo could shrink tumors and to check its safety. The trial was terminated…

This phase 2 trial tested a combination of two drugs, niraparib and dostarlimab, in 51 adults with advanced solid tumors that had DNA repair defects or were sensitive to platinum chemotherapy. The goal was to see if the combo could shrink tumors. However, the study was terminated…

This trial tested a combination of two drugs, rucaparib and atezolizumab, in 130 adults with advanced solid tumors that have specific DNA repair problems or are sensitive to platinum chemotherapy. The goal was to see if the combination could shrink tumors. However, the study was …

This study looked at whether adding an immunotherapy drug (pembrolizumab) to a targeted therapy (pemigatinib) works better than the targeted therapy alone or standard care for people with advanced bladder cancer that has a specific gene change (FGFR3). The study was stopped early…

This early-phase study tested the safety of an oral drug called LY3405105 in 54 people with advanced solid tumors. The trial was divided into two parts to find the right dose and to see if the drug could shrink tumors. However, the study was terminated early, meaning the drug did…

This phase 2 study tested several drug combinations (retifanlimab, epacadostat, INCAGN02385, INCAGN02390) given before bladder removal surgery in 30 patients with muscle-invasive bladder cancer who could not take the standard chemo drug cisplatin. The trial was terminated early, …

This study tested whether adding the immunotherapy drug avelumab to standard radiation could help treat muscle-invasive bladder cancer in patients who cannot receive the usual chemotherapy. Fourteen participants received the combination therapy. The goal was to see if the cancer …

This trial tested whether adding gemcitabine to standard cisplatin and radiation therapy could help control muscle-invasive bladder cancer while preserving the bladder. About 69 patients were enrolled to compare the combination against standard treatment. The study was terminated…

This small phase II study tested whether combining the chemotherapy drug docetaxel with the targeted therapy lapatinib could help patients with advanced bladder cancer that had already been treated with platinum-based chemo. Only 15 people enrolled before the study was terminated…

This phase 2 trial tested the drug tovorafenib (DAY101) in 23 people aged 12 and older with recurrent or progressive solid tumors that have specific genetic changes in the MAPK pathway. The goal was to see how many patients' tumors shrank or disappeared. The study was terminated …

This phase 3 trial tested whether adding nivolumab (an immunotherapy drug) to standard BCG treatment could help people with high-risk bladder cancer that came back after BCG alone. Only 13 people enrolled before the study was stopped early, so we don't have clear results on wheth…

This phase 2 trial tested whether adding trilaciclib (Cosela) to standard chemotherapy and avelumab could help people with advanced bladder cancer by protecting their bone marrow. The study enrolled 92 adults with untreated, locally advanced or metastatic urothelial carcinoma. Un…

This study is testing the NXT Urodynamics System, a device used to measure how well the bladder stores and releases urine. Researchers want to confirm it is safe and works correctly in people with bladder problems like incontinence or overactive bladder. About 180 adults who need…

This study tested a urine test that measures a protein called DEK to help diagnose bladder cancer. It included over 1,100 people with blood in their urine or painful urination. The goal was to see if the test could accurately detect cancer without invasive procedures. However, th…

This study looked at women with pelvic organ prolapse who also had hidden (occult) stress urinary incontinence — leakage that doesn't show up on standard tests. The goal was to see if placing a TOT sling during prolapse surgery could prevent incontinence from appearing later. The…

This study looks at whether yoga can improve overactive bladder symptoms in children aged 8 to 18. Participants attend a weekly yoga session for 6 weeks. Researchers will track symptom changes using questionnaires and urine tests. The goal is to find a gentle, non-drug option for…

This pilot trial investigates whether low-dose naltrexone (LDN) can reduce pain and urinary symptoms in people with bladder pain syndrome or interstitial cystitis. Participants receive either LDN or a placebo nightly for 8 weeks. The study measures pain scores, urinary frequency,…

This pilot study tested whether MitoQ, an antioxidant supplement, could improve bladder symptoms like urgency and frequency in women aged 50 and older with metabolic syndrome. Twenty participants took either MitoQ or a placebo for 4 months, tracking their symptoms through questio…

This study looked at whether a combined treatment plan—including physical therapy, behavioral health therapy, and medical procedures—could reduce symptoms of chronic bladder pain. Researchers compared this bundled approach to usual care in 26 women with interstitial cystitis or b…

This study tested a reusable vaginal pessary device to help women with stress urinary incontinence (leaking urine when coughing, sneezing, or exercising). Each woman acted as her own control, comparing leak amounts with and without the device. The study was terminated early and o…

This study looked at whether a special protocol used by community pharmacists in France can help women with simple bladder infections (cystitis) get relief more quickly. The goal was to reduce symptoms and avoid unnecessary trips to the doctor or emergency room. The study include…

This Phase 2 trial tested a neuroscience-based technique combining memory structuring and deep vagal breathing to reduce PTSD symptoms in people with advanced, incurable cancer and their partners. The study enrolled 19 patients who had just received a terminal diagnosis. The appr…

This study tested a single dose of URG101, a combination of lidocaine and heparin, to see if it safely reduces bladder pain in people with Interstitial Cystitis/Bladder Pain Syndrome. The trial was randomized and double-blind, meaning neither patients nor doctors knew who got the…

This study tested a new type of catheter for men who need long-term catheters due to urinary retention. The CymActive catheter has a magnetic valve that lets users control when they urinate, unlike standard catheters that drain continuously. The study aimed to see if it was more …

This study looks at how adults with bladder problems decide which Coloplast catheter (SpeediCath or Luja) works best for them when they start self-catheterization. Researchers will track satisfaction and challenges over six months. The goal is to help healthcare providers recomme…

This early study tests a new approach for stress urinary incontinence (leaking urine when coughing, sneezing, or exercising). Researchers will stimulate nerves near the urethra in 20 women to see if it increases urethral pressure, which could help prevent leaks. The goal is to un…

This study followed 202 bladder cancer patients who were prescribed Adstiladrin (nadofaragene firadenovec) in real-world clinics in the US and Israel. Researchers wanted to see how often the drug led to complete remission and how long that lasted. The study was terminated early, …

This study looked at whether genetic changes found in urine could match those in tumor tissue for people with high-risk non-muscle invasive bladder cancer. The goal was to see if a urine test could help doctors choose the best immunotherapy for each patient. The study planned to …